CiVi Biopharma Takes $40M

San Francisco-based biopharmaceuticals developer CiVi Biopharma, a biopharmaceuticals firm which is targeting cardiometabolic diseases, has raised $40M in a funding round, the company said on Friday

The story you have requested is only available to paid members of the web site. Stories newer than 15 days are restricted to paid members only. Please login in order to access this members-only content, or become a member.